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ABSTRACT

Vaccines for pathogenic Strains of bovine herpesvirus 1

(BHV-1) which are based on attenuated BHV-1 having a
mutation in the latency-related gene are provided. Live,
attenuated vaccines are also provided which express anti
gens from other viral or bacterial pathogens and thus form
the basis of a variety of vaccines.
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WACCNES CONTAINING BOVINE HERPESVIRUS
1 ATTENUATED BY MUTATION IN
LATENCY-RELATED GENE

are disadvantages associated with the use of currently avail
able vaccines, for example, they can cause disease in young
calves or abortions in cows, and all have the potential to

CROSS-REFERENCE TO RELATED
APPLICATIONS

establish latency and reactivate from latency (Jones et al.,
2000).
0006. In order to overcome these disadvantages,

0001. This application is based on U.S. Provisional
Application Serial No. 60/437,855, filed on Jan. 3, 2003
which is hereby incorporated herein by reference.

improved live attenuated vaccines that are effective against
BHV-1 and other viral and bacterial pathogens, and which
will not reactivate from latency, are needed.

STATEMENT REGARDING FEDERALLY
SPONSORED RESEARCH OR DEVELOPMENT

BRIEF SUMMARY OF THE INVENTION

0002 This invention was made with government support
under grants from the U.S. Department of Agriculture,
numbers 9802064 and 2000-02060 and grant number
P2ORR15635 from the National Institutes of Health. The

government has certain rights in this invention.
BACKGROUND OF THE INVENTION

0003. The present invention relates generally to vaccines
based on live, attenuated viruses and to methods of using
these vaccines. More particularly, the present invention
relates to vaccines based on bovine herpesvirus 1, attenuated
by mutation in the latency-related gene, and to methods for
using these vaccines to induce immunological response to
BHV-1 Specific and/or recombinant immunogenic antigens
without reactivation of the virus from latency.
0004. The publications and other materials used herein to
illuminate the background of the invention or provide addi
tional details respecting the practice, are incorporated by
reference, and for convenience are respectively grouped in
the appended List of References.

0005) Bovine herpesvirus 1 (BHV-1) is an important viral
pathogen of cattle that can cause Severe respiratory infec
tion, conjunctivitis, abortions, Vulvovaginitis, balanoposthi

tis, and Systemic infection in neonate calves (Wyler et al.,
1989). BHV-1 infection is also an important component of

the upper respiratory tract infection referred to as "shipping

fever” or bovine respiratory complex (Tikoo et al., 1995).
BHV-1 is not the sole infectious agent associated with
Shipping fever, but it initiates the disorder by immuno
Suppressing infected cattle, which results in Secondary bac
terial infections and pneumonia. Increased Susceptibility to
Secondary infection correlates with depressed cell-mediated

immunity after BHV-1 infection (Carter et al., 1989; Griebel
et al., 1990; Griebel et al., 1987A; Griebel et al., 1987B).

CD8" T-cell recognition of infected cells is impaired by
repressing expression of major histocompatibility complex
class I and of the transporter associated with antigen pre

0007. It is an object of the present invention to provide
live viral vaccines based on BHV-1 attenuated by mutation

in the latency-related (LR) gene so that the BHV-1 does not
reactivate from latency. These live, attenuated Viral vaccines
cause acute infection and produce Sufficient viral titer to
elicit a cell-mediated immune response.
0008. It is another object of the present invention to
provide live viral vaccines based on BHV-1 attenuated by
mutation in the LR gene which express recombinant immu
nogenic antigens. These attenuated viral vaccines cause
acute infection and produce a specific antibody response to
the recombinant antigens. The recombinant antigens may be
one or more BHV-1 antigens or antigens of other viral or
bacterial pathogens, or both.
0009. It is a further object of the present invention to
provide methods for effecting prophylactic treatment of viral
or bacterial infection through the use of the live, attenuated
Viral vaccines of the present invention, wherein the vaccine
is administered to an animal in need of treatment and

induces immunological response to viral or bacterial patho
genS.

0010. According to the present invention, the foregoing
and other objects are achieved by the discovery, as described
in further detail herein, that the LR gene of BHV-1 is
necessary for reactivation of the virus from latency, and that
the LR mutant of BHV-1 is able to grow and cause acute
intranasal infection, and is therefore able to elicit an immu

nological response in an infected animal. The vaccines of the
present invention utilize live BHV-1, attenuated by mutation
of the LR gene, to express BHV-1 specific and/or recombi
nant immunogenic antigens and, thus, induce immunologi
cal response to viral and bacterial pathogens. The vaccines
of the present invention may be administered using one or
more routes, including, but not limited to, Subcutaneous,
intramuscular, intranasal, intraperitoneal, and ocular.
BRIEF DESCRIPTION OF THE DRAWINGS

sentation (Hariharan et al., 1993; Hinkley et al., 1998;
Naturaj et al., 1997). CD4" T-cell function is impaired

0011 FIG. 1 shows isolation and titration of virus
present in trigeminal ganglia (TG) during acute infection.

during acute infection of calves, in part, because BHV-1

type (WT) infected calves on the designated days postin

infects CD4 T cells and induces apoptosis (Winkler et al.,
1999). BHV-1 infection costs the cattle industry millions of

dollars per year in the United States. Following acute
infection, BHV-1 establishes lifelong latency in ganglionic
neurons of the peripheral nervous System after initial repli
cation in mucosal epithelium. Reactivation from latency
results in Virus Shedding and transmission to other Suscep
tible animals. Reactivation occurs after natural or corticOS

teroid-induced stress (Rock et al., 1992; Sheffy and Davies,
1972). Although modified live vaccines are available, there

Virus was isolated from TG of mock, LR mutant, or wild

fection, as further described in Example 1. The titer of
infectious virus was determined on bovine kidney cells

(MDBK) as described in Example 1. The data shown are the

averages from each group. A value of 0.2 was used to denote
a negative result in order to visualize the bars.
0012 FIG. 2 shows DNA sequences of the wild-type

(wt) (SEQ ID NO:7) and LR mutant (SEQ ID NO:8). DNA

was prepared from TG as described in Example 1. Primers

P4 and P5 (Inman et al., 2001B) were used to amplify a
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region that contains the mutated Sequences, including a
unique EcoRI site. The amplified products were then

digested with EcoRI (position in LR mutant is underlined)

and visualized by ethidium bromide Staining on 2% agarose
gel electrophoresis.
0013 FIG. 3 shows BHV-1 neutralizing antibody titers
post infection and after DEX treatment, as indicated, mea
Sured as described in Example 1. Solid rectangles represent
calves infected with wt virus, Solid triangles represent
LR-rescued virus, and open rectangles represent calves
infected with the LR mutant virus. Each time point repre
Sents at least four calves. The inset panel is shown to
illustrate the differences during acute phase more clearly

(the x-axis scale is altered). The differences between the
time points after 10 days postreactivation were Statistically
significant (P<0.05).
0.014 FIG. 4 shows viral shedding from ocular and nasal
cavities after dexamethasone-induced reactivation deter

mined using the procedures of Example 1. Shown are the
percentages of calves that shed BHV-1 virus/total number of
calves in each group on the designated day after dexam

ethasone (DEX) treatment. Four calves were used for the
study with the LR-rescued virus, seven were used for the wt
(WT) study, and seven were used for the study with the LR
mutant.

SUMMARY OF THE SEQUENCES

0015 SEQID NO:1 is the nucleotide sequence for primer

p4.

0016 SEQID NO:2 is the nucleotide sequence for primer
p5.
0017 SEQ ID NO:3 is the nucleotide sequence for for
ward primer gC.
0018 SEQ ID NO:4 is the nucleotide sequence for
reverse primer gC.
0019 SEQ ID NO:5 is the nucleotide sequence for for
ward primer gh.
0020 SEQ ID NO:6 is the nucleotide sequence for
reverse primer gh.
0021 SEQ ID NO:7 is the nucleotide sequence of the
wild-type BHV-1 latency-related ORF2 shown in FIG. 2.
0022 SEQID NO:8 is the nucleotide sequence of the LR
mutant oligonucleotide shown in FIG. 2.
DETAILED DESCRIPTION OF PREFERRED
EMBODIMENT

0023 The present invention is directed to live, attenuated
vaccines based on BHV-1 attenuated by mutation in the

latency-related (LR) gene. The discovery, described in detail

herein, that the LR gene of BHV-1 is not required to
establish acute intranasal infection, and that the LR gene is
essential for reactivation of BHV-1 from latency, makes
possible the construction of live attenuated BHV-1 vaccines
which are capable of inducing immune responses without
reactivation from latency.
0024. In one embodiment, the vaccines of the present
invention provide immune System exposure to epitopes on
the attenuated BHV-1 virus and induce immunological
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response to pathogenic strains of BHV-1. In another embodi
ment, the vaccines of the present invention provide immune
System exposure to one or more recombinant antigens of
BHV-1 and/or other pathogenic viruses or bacteria. The
present invention can be practiced with a variety of Viral and
bacterial pathogens, including, without limitation, those
which colonize and grow in the upper respiratory tract or
other mucosal Surfaces. Examples of Such pathogens include

bovine viral diarrhea virus (BVDV), bovine respiratory
virus (BRSV), bovine corona viruses, and bacterial strains
commonly associated with “Shipping Fever” (Pasteurella
haemolytica, Pasteurella multocida, and Haemophilus SOm

nus for example). The vaccines of the present invention are

useful with mammals, preferably ungulates, most preferably
with sheep, bovines, deer, and buffalo.
0025 The present invention is further directed to meth
ods for effecting treatment of infections through adminis
tration of the vaccines of the present invention to induce
immunity in an animal in need of treatment. In one embodi
ment, the treatment is of a BHV-1 infection. In another
embodiment, the treatment is of infection with a different

pathogenic virus or a pathogenic bacterium.
0026 BHV-1 is a member of the Alphaherpesvirinae
Subfamily and shares certain biological properties with

herpes simplex virus types 1 and 2 (HSV-1 and -2, respec
tively) (Jones 1998). Viral gene expression in BHV-1 is
temporally regulated in three distinct phases: immediate

early (IE), early (E), or late (L). Two IE transcription units
exist: IE transcription unit 1 (IEtu1) and IEtu2. IEtu1
encodes functional homologues of two HSV-1 IE proteins,
ICP0 and ICP4. IEtu2 encodes a protein that is similar to an

essential HSVIE protein, ICP22 (Wirth et al., 1991). Bovine
ICP0 (bCPO) is very important for productive infection,

because it activates all classes of viral promoters and is

expressed at high levels throughout infection (Fraefel et al.,
1994; Wirth et al., 1992; Wirth et al., 1991).
0027) Although the primary site of BHV-1 latency is
Sensory neurons, there is evidence that long-term persistence
and reactivation also occur within germinal centers of pha

ryngeal tonsil (Winkler et al., 2000). The latency-related
RNA (LR-RNA) is the only abundant viral transcript
detected in latently infected neurons (Kutish et al., 1990;
Rock et al., 1992; Rock et al., 1987A). A fraction of
LR-RNA is polyadenylated and alternatively spliced in
trigeminal ganglia (TG), Suggesting this RNA is translated
into more than one LR protein (LRP) (Devireddy and Jones,
1998; Hossain et al., 1995). LR gene products effect the
normal cell cycle by inhibiting entry into S-phase. LRP is
associated with cyclin-dependent kinase 2 (cdk2)-cyclin
complexes (Hossain et al., 1995; Jiang et al., 1998). LR gene
products also promote cell Survival following induction of

apoptosis in transiently transfected cells (Ciacci-Zanella et
al, 1999).
0028. Similar to BHV-1, HSV-1 establishes latency in

ganglionic Sensory neurons, typically TG or Sacral dorsal

root ganglia (Jones 1998; Wagner and Bloom, 1997). In situ
hybridization has revealed that a Small region, the latency

associated transcript (LAT), within the terminal repeats is
abundantly transcribed in latently infected neurons (Rocket
al., 1987B; Stevens et al., 1987). Numerous mutants that do

not express detectable levels of LAT have been constructed.
Although Several Studies have Suggested that LAT plays no
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role in a latent infection, for example (Blocket al., 1990; Ho
and Mocarski, 1988), most have concluded that LAT is
important, but not required. LAT enhances establishment of
latency in mice (Sawtell, 1992; Thompson and Sawtell,
1997) and rabbits (Perng et al., 2000B), because certain
LAT-null mutants contain lower levels of viral DNA in TG

relative to wt virus (Devi-Rao et al., 1994; Maggioncalda et
al., 1996). LAT interferes with apoptosis in transiently
transfected cells and in infected mice or rabbits (Ahmed et
al., 2002; Inman et al., 2001A; Perng et al., 2000A). The
ability of LAT to interfere with apoptosis correlates with its
ability to promote spontaneous reactivation (Inman et al.,
2001A), Suggesting the antiapoptotic activity of LAT has

biological significance with respect to latency.
0029. Although the LR gene of BHV-1 is homologue of
the HSV-1 LAT gene, there are several notable differences.
Most notably, the evidence presented herein shows that LR
mutant BHV-1 does not reactivate from latency. In contrast,
LAT-null mutants have been reported to reactivate from
latency. Furthermore, the primary LAT transcript is 6.3 kb

and includes two genes (Zwaagstra et al., 1990), whereas the
primary LR transcript is only 1.5 kb and one gene (Kutish
et al., 1990), and there is no obvious sequence homology
between LR-RNA and LAT. While the region of LAT to
which the Spontaneous reactivation phenotype maps does
not appear to encode a protein involved in the latency

reactivation cycle (Dorlet et al., 1998), the BHV-1 LR gene
does encode Such a protein (Jiang et al., 1998). Although an
open reading frame in the stable 2-kb LAT may encode a
protein (Coffin et al., 1998; Thomas et al., 1999), this protein
is unlikely to play an important role in reactivation Since it
is located outside the region of LAT to which the reactiva

tion function maps in rabbits (Bloom et al., 1996; Perng et
al., 2001) and mice. Expression of an LR protein appears to
play a role in protecting cells from death (Ciacci-Zanella et
al., 1999). Finally, the LR gene has also been shown to
inhibit cell cycle progression (Schang et al., 1996) and in the
context of the Viral genome plays an important role in Virus

shedding in the eyes of infected calves (Inman et al., 2001).

Thus, structurally, the LR and LAT genes and RNAS are very
different.

0030) Definitions.
0031. The present invention employs the following defi
nitions, which are, where appropriate, referenced to BHV-1.
0032. An “antigen” refers to a molecule containing one or
more epitopes that will Stimulate a host's immune System to
make a Secretory, humoral and/or cellular antigen-Specific
response.

0033. The specific antigen can be a protein, a polysac
charide, a lipopolysaccharide or a lipopeptide; or it can be a
combination of any of these. Particularly, the Specific anti
gen can include a native protein or protein fragment, or a
Synthetic protein or protein fragment or peptide; it can
include glycoprotein, glycopeptide, lipoprotein, lipopeptide,
nucleoprotein, nucleopeptide; it can include a peptide-pep
tide conjugate; or it can include a recombinant nucleic acid
expression product. Examples of antigens include, without
limitation, those that are capable of eliciting an immune
response against Viral or bacterial bovine herpes virus,
bovine respiratory virus, bovine viral diarrhea virus, bovine
corona virus, and bacterial Strains commonly associated
with “shipping fever”.

0034. The term “effective amount of an antigen” may be
an amount capable of eliciting a demonstrable humoral,
Secretory, and/or cell-mediated immune response. The
appropriate amount of antigen to be used is dependent on the
Specific antigen and is well known in the art.
0035 “Encode.” A polynucleotide is said to “encode” a
polypeptide if, in its native State or when manipulated by
methods well known to those skilled in the art, it can be

transcribed and/or translated to produce the mRNA for the
polypeptide and/or a fragment thereof. The anti-Sense Strand
is the complement of Such a nucleic acid, and the encoding
Sequence can be deduced therefrom.
0036) “Immunization” refers to the process of inducing a
continuing protective level of antibody and/or cellular
immune response which is directed against an antigen to
which the organism has been previously exposed.
0037. An “immunological response' to a vaccine is the
development in the host of a humoral, Secretory, and/or
cell-mediated immune response to the vaccine of interest.
An immunological response is usually assayed with an
immunoassay. A variety of immunoassay methods are well
known in the art. See, e.g., Harlow and Lane, 1988, or
Goding, 1986.
0038 “Latency-reactivation cycle” refers to a process
operationally divided into three major Steps: establishment
of latency, maintenance of latency, and reactivation. Estab
lishment of latency includes entry of the viral genome into
a Sensory neuron and acute infection. In BHV-1, Viral gene
expression is then generally extinguished, with the excep

tion of the latency-related transcript (LR). Maintenance of
latency is a phase that lasts for the life of the host and can
be operationally defined as a period when infectious virus is
not detected by Standard virus isolation procedures. In
general, abundant expression of Viral genes that are required
for productive infection does not occur during maintenance
of latency. LR is the only known viral transcript that is
abundantly expressed during this stage of latency. “Reacti
vation” and “reactivation from latency” refer to the process
of Viral reactivation which and Stimulation of viral gene
expression which occurs after exogenous administration of
corticosteroids or elevated levels of natural corticosteroids

as a consequence of StreSS. The Synthetic corticosteroid

dexamethasone (DEX) efficiently reactivates BHV-1 in
latently infected rabbits and calves (Rocket al., 1992; Sheffy
and Davies, 1972). Immunosuppression may also stimulate

Viral gene expression to cause reactivation. Upon reactiva
tion, abundant Viral gene expression may be detected in
sensory neurons, and infectious BHV-1 virus can be isolated
from TG, eye Swabs, and/or nasal Swabs. During reactiva
tion, Virus is translocated back to the initial Site of infection,

from which it can spread to other susceptible hosts. The
ability to reactivate from latency results in recurrent disease
and virus transmission.

0039 “Operably linked” refers to a juxtaposition of com
ponents wherein the components So described are in a
relationship permitting them to function in their intended
manner. For instance, a promoter is operably linked to a
coding Sequence if the promoter affects its transcription or
expression.
0040) “Recombinant nucleic acid” is a nucleic acid which
is not naturally occurring, or which is made by the artificial

US 2004/0185056A1

combination of two otherwise Separated Segments of
Sequence. This artificial combination is often accomplished
by either chemical Synthesis means, or by the artificial
manipulation of isolated Segments of nucleic acids, e.g., by
genetic engineering techniques. Such is usually done to
replace a codon with a redundant codon encoding the same
or a conservative amino acid, while typically introducing or
removing a Sequence recognition site. Alternatively, it is
performed to join together nucleic acid Segments of desired
functions to generate a desired combination of functions. A
polypeptide produced as an expression product of an iso
lated and manipulated genetic Sequence is an "isolated
polypeptide', as used herein, even if expressed in a homolo
gous cell type. Synthetically made forms or molecules
expressing by heterologous cells are inherently isolated
molecules.

0041 A“recombinant vector' of the present invention is
a live BHV-1 virus attenuated by mutation in the latency
related gene and expresses recombinant immunogenic anti
gens of one or more pathogen.
0.042 “Treatment” refers to the administration to an indi
vidual of a composition which yields a immunological
response, and includes prophylaxis and/or therapy.
0.043 “Vaccine composition” and “vaccine” refer to an
agent used to Stimulate the immune System of an individual
So that current harm is alleviated, or protection against future
harm is provided.

0044 As described in further detail herein (Example 4),
and in Perng et al. (2002), incorporated herein in its entirety
by reference, the LR gene was inserted into the LAT locus
to determine whether it could restore Spontaneous reactiva
tion to a LAT-null mutant. It has been discovered that the LR

gene of BHV-1 is capable of restoring high levels of
Spontaneous reactivation from latency to a LAT-null mutant,
adding Support to the hypothesis that inhibition of apoptosis
plays an important role in the latency reactivation cycle of
HSV-1 and BHV-1.

0.045 An LR mutant was constructed by inserting three
Stop codons near the beginning of the LR-RNA, Suggesting
that expression of LR proteins would be altered. The LR

mutant grew with wild-type (wt) efficiency in bovine kidney
cells (MDBK). Calves infected with the LR mutant consis

tently exhibited diminished clinical Symptoms and a dra

matic decrease (3 to 4 logs) in ocular, but not nasal, viral

Shedding occurred during acute infection compared to the wt

or the LR-rescued virus (Inman et al., 2001). Conversely, the
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by PCR, we were unable to detect viral DNA in neurons of
calves infected with the LR mutant by in situ hybridization.
PCR analysis confirmed that calves infected with the LR
mutant contained lower levels of viral DNA during latency
compared to those in calves infected with wt BHV-1. The
evidence reported herein further shows that the LR mutant
Virus was not reactivated from latently infected calves

following treatment with dexamethasone (DEX). In con
trast, calves infected with wt virus or the LR-rescued virus

reactivated efficiently following the same DEX treatment.
The results described herein demonstrate that wt expression
of LR gene products plays a crucial role in the latency
reactivation cycle of BHV-1 in cattle.
0047 As described herein in further detail, the LR mutant
did not reactivate from DEX-induced reactivation, whereas
the wt or LR-rescued virus did. The LR mutant contains

three stop codons near the beginning of the LR-RNA that are
designed to prohibit protein expression from all three read

ing frames (Inman et al., 2001B). The LR mutant also lacks

25 bp from Wt Sequence to prevent reversion to the wt. A
peptide antibody that is directed against amino acid

Sequences within the LR open reading frame (ORF2) rec
ognizes a protein of approximately 40 kDa in cells trans

fected with a wt LR gene construct (Ciacci-Zanella et al.,
1999; Hossain et al., 1995; Jiang et al., 1998), but not when
transfected with a plasmid containing the mutation used to

make the LR mutant virus (Ciacci-Zanella et al., 1999).

While not wanting to be bound by any particular theory, it
appears that any phenotypic difference between the LR
mutant and wt or LR-rescued virus is attributable to lack of

protein expression by the LR mutant. Because the LR-RNA

is alternatively spliced (Devireddy and Jones, 1998), there is
the possibility that more than one protein is expressed.
However, it is possible that differences in LR-RNA expres
sion between wt BHV-1 and the LR mutant were responsible
for the attenuated phenotype. Regardless of whether an LR
protein or changes in LR-RNA mediate the altered pheno
type of the LR mutant, the results reported herein clearly
demonstrated that the latency reactivation cycle was dis
rupted following infection of calves with the LR mutant.

0048. The TG is divided into three sections (ophthalmic,
maxillary, and mandibular), and each Section innervates the

eye, nose, or mouth, respectively. Following infection of
calves with the LR mutant, a 3- to 4-log reduction in Virus
Shedding from ocular Swabs was detected compared to the

level in calves infected with wt or LR-rescued virus (Inman
et al., 2001B). In contrast, shedding of the LR mutant from

LR mutant had similar growth properties in productively

the nasal cavity during acute infection was not significantly

infected bovine kidney cells (MDBK) and the nasal cavity of

Without being bound to a particular mode of action, the
results reported herein Suggest that “Seeding of the TG by
the LR mutant would be fairly normal via the maxillary
route following infection, but lower levels of virus would
seed the TG via the ocular route. Considering that it was not
possible to reactivate the LR mutant and lower levels of viral
DNA were detected in TG of calves latently infected with
the LR mutant, it may be that seeding of viral DNA via the
ocular route is more important. It is also possible that
regardless of whether the LR mutant seeds the TG via the
maxillary or ocular route, efficient amplification of the viral
genome or reactivation from latency would not occur. The
finding that 10- to 100-fold less infectious virus was present
in TG of calves acutely infected with the LR mutant supports

calves during acute infection. These results Suggested that
LR gene products promote virus growth in certain cell types
in the eye or optic nerve during acute infection of cattle.
0046) The evidence presented herein compares the
latency reactivation cycle in calves infected with the LR

mutant and to those from calves infected with wt BHV-1 or

the LR-rescued virus. This application reports the results of
examining the effects of the LR mutant on Virus production
in TG and the latency reactivation cycle. Diminished levels
of virus were detected in TG of calves acutely infected with
the LR mutant when compared to those infected with wt or
LR-rescued virus. Although we consistently detected LR
RNA in TG of calves infected with the LR mutant or the wt

different from that of wt BHV-1 or the LR-rescued virus.

US 2004/0185056A1

the contention that wt expression of LR gene products was
important for acute infection of Sensory neurons.
0049. Several reports have demonstrated that HSV-1 LAT

plays an important role in establishing (versus reactivation)
latency (Perng et al., 2000B; Sawtell, 1997; Sawtell, 1992),

Suggesting LR gene products also play a role in establishing
latency. Two findings in this Study Support a role for wt
expression of LR gene products in the establishment of
latency. First, reduced levels of viral DNA were detected in
calves latently infected with the LR mutant. Second, the
failure to detect in Situ hybridization-positive neurons in
calves latently infected with the LR mutant Suggested that
LR gene products were necessary for latency in neurons
containing high copies of viral DNA. While not wanting to
be bound by a particular mode of action, it is possible that

LR gene products promote (i) productive infection in certain
neurons, (ii) Survival of "permissive' neurons that Support
productive infection, or (iii) infection of certain types of

neurons. Considering that LR gene products interfere with

apoptosis in transiently transfected cells (Ciacci-Zanella et
al, 1999) and HSV-1 LAT interferes with apoptosis (Ahmed
et al., 2002, Inman et al., 2001A; Perng et al., 2000A), it is

tempting to speculate that LR gene products promote neu
ronal Survival in TG of infected calves during acute infec
tion.

0050 Infectious virus was not detected in calves latently
infected with the LR mutant following DEX treatment to

initiate reactivation (FIGS. 3 and 4). No changes in virus

Specific antibodies were detected during the course of reac
tivation. An increase in Virus-specific antibodies is a Sensi

tive method to detect reactivation from BHV-1 (Jones et al.,
2000) and HSV-1 (Perng et al., 1999). Furthermore, multiple
injections of DEX were used to ensure that reactivation
occurred. By using a similar protocol, a modified live
vaccine strain of BHV-1 that is severely attenuated has been

reactivated (Jones et al., 2000). It is generally accepted that
the amount of viral DNA in TG of HSV-1-infected Small

animal models plays a role in the efficiency of reactivation

(Jones 1998; Wagner and Bloom, 1997), implying there is a
similar mechanism for BHV-1. As discussed above, calves
infected with the wt, but not the LR mutant, have neurons

with high levels of viral DNA and reactivate efficiently.
0051). In general, HSV-1 LAT has been shown to be
important, but not required, for latency reactivation in

rabbits and mouse models (Jones 1998; Wagner and Bloom,
1997). The results reported herein show that wt expression
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not been described for HSV-1 LAT. The LR gene restores
Spontaneous reactivation to a McKrae LAT-null mutant

(dLAT2903), demonstrating that LAT and LR gene products

have common functional properties that are necessary for

efficient reactivation from latency (Perng et al., 2002). In

addition, the LR gene enhanced the ability of dLAT2903 to
kill mice during acute infection and induce recurrent eye
disease in latently infected rabbits, underScoring our hypoth
esis that LR gene products have expanded roles during the
latency reactivation cycle and even pathogenesis when com
pared to LAT.
0.052 Method of Use: Vaccines for Bovine Herpesvirus 1
0053 Novel BHV-1 vaccines of the present invention are

based on the discovery that: 1) the LR gene of BHV-1 is not
required to establish acute intranasal infection; and 2) the

LR gene is essential for reactivation of BHV-1 from latency.
The present invention accordingly seeks to provide novel
vaccines based on live BHV-1, attenuated by mutation in the
latency-related gene, which elicit an immune response in the
host, however do not reactivate from latency.
0054 BHV-1 strains comprising a mutation in the LR
gene are provided. The mutation can be obtained by means
well known in the art, Such as but not limited to, genetic
engineering techniques, chemical Synthesis, mutant Selec
tion techniques, or the method described in Example 2. Any
methods which do not interrupt blCP0 gene expression, yet
interrupt LR gene expression, may be employed.
0055. In a preferred method, the mutant oligonucleotide

is inserted into the Cooper strain of BHV-1 (ATCC No.
VR-864). In addition to the LR mutation, one or more

additional deletions or modifications to the coding
Sequences of a glycoprotein are preferably included to
further attenuate the Cooper Strain of BHV-1. Examples of
BHV-1 glycoprotein genes that can be deleted, or modified
by insertion, Substitution or otherwise are: glycoprotein C,
glycoprotein D, glycoprotein E, glycoprotein G, glycopro
tein H, or glycoprotein I. Although this is a preferred
embodiment, other means to arrive at an LR-null mutant

may be used in the practice of the invention. Further, a
mutant LR gene could be inserted into other commercially
available strains of BHV-1, for example, without limitation,

BovaShield (Pfizer, Inc.) or the temperature sensitive mutant
described in Jones et al. (2000). In one preferred embodi
ment, the BHV-1 strain is less virulent than the Cooper strain
of BHV-1. Further mutations may be made using the plas

of LR gene products was required for the latency reactiva
tion cycle in calves when reactivation was initiated by DEX.
One possible explanation for this is that the LR gene is more
important than LAT for the latency reactivation. BHV-1
lackS. Several genes contained in the HSV-1 genome, which
mediate pathogenesis and/or latency: the 34.5 gene, for

mid (pBlueL/mLAT) (Inman et al., 2001B). Briefly, plasmid
(pBlueL/mLAT) can be constructed as follows: 825 base
pairs (bp) of the BHV-1 HindIII L fragment that is directly
upstream of the LR promoter (D fragment) are cloned into
pBlueBachis.A (InVitrogen, Carlsbad, Calif.), pBR322-Hin

example (Schwyzer and Ackermann, 1996). The 34.5 gene

(Cooper Strain) and this plasmid is digested with NheI. The

plays a crucial role in neurovirulence by inhibiting antiviral
functions of the interferon-inducible double-stranded RNA

dependent protein kinase R (Chou et al., 1995; Leib et al.,
2000). 34.5-null mutants have reduced pathogenesis in rab

bits and mice, in large part because of poor growth proper

ties in the eyes and TG (Perng et al., 1995). Since LR gene

products play a role in ocular growth of BHV-1 in calves

(Inman et al., 2001B) and lower levels of infectious virus
mutant (FIG. 1), they have additional properties that have

were detected in TG of calves acutely infected with the LR

dIII L-fragment contains the HindIII L fragment of BHV-1
resulting products are treated with Mung Bean exonuclease

(New England BioLabs) to blunt the ends for ligation of
BamHI linkers. After phenol and chloroform extraction, the
DNA is digested with HindIII and then BamHI. The prod
ucts are electrophoresed on an agarose gel and the 825 bp
product isolated. The 825bp product containing a 5' BamHI
site and a 3' Hind III site is ligated into the pBlueBachis

vector digested with BamHI plus HindIII (resulting plasmid
designated herein as pBlueL). A fragment containing the
entire LR promoter and coding region (1940 bp) is cloned

Sep. 23, 2004

US 2004/0185056A1

into the HindIII and Sall sites of pBlueL (resulting plasmid
designated herein as pBlueL/LAT). The PstI fragment
(1-981 nt) is excised from pBlueL/LAT and cloned into

pBlueBachis vector. This sub-cloning is performed because
there are 3 SphI sites in the coding region of the LR gene

(781, 812 and 1777 nt). The SphI fragment (781-812 NT) is

excised and the mutant oligonucleotide inserted. The
mutated Pst fragment is then cloned back into the original

PstI digested pBlueL/LAT and the resulting construct (des
ignated herein as pBlueL/mLAT). Restriction enzyme map

ping and DNA sequencing can be used to determine proper
orientation of the Pst fragment. All cloning procedures

(restriction digests, ligations, CIP treatment, etc.) are per

formed by standard procedures. All BHV-1 fragments can be

obtained from the Cooper strain of BHV-1 (ATCC VR-864).
0056. The coding sequences for the glycoprotein genes
listed above are known, and primers can be designed to
amplify these genes. Deletions can be generated using
Standard molecular biology techniqueS Such as restriction
enzyme digestions, PCR mediated mutagenesis, or site
directed mutagenesis. These deletions are introduced back
into the Cooper Strain using homologous recombination, as
described in Example 2 for constructing the LR mutant.
0057 Bovine epidermal cells are cotransfected with 6 ug
pBlueL/mLAT, 2 ug of a plasmid encoding HSV-1 ICP0, and

2 ug of Viral DNA using Superfect (Qiagen) as previously
described (Inman et al., 2001B, Inman et al., 2002). Sixteen
hours after transfection, cells are split 1:2, incubated for 16
additional hours, and then overlaid with 0.7% Seaplaque
agarose. When visible plaques appear (3-4 days after infec
tion); each plaque is isolated, propagated in MDBK cells,
and screened by PCR for the mutant oligonucleotide insert.

PCR is performed on the extracted DNA using primer 4 (p4)
(nt 873 5'CGTGTATTTGCGACCCCCAGCCT3) and
primer 5 (p5) (nt 596 5'GCCAGACCAAAC
CCCCCGCA3). After a hot start, each cycle consists of 95
C. for 1 min., 60° C. for 1 min. and 72° C. for 2 min. (30
cycles total). To ensure complete elongation of amplified
products, the reaction is incubated at 72 C. for an additional
10 minutes. Products are digested with EcoRI, electrophore
Sed on a 2% agarose gel, and the DNA visualized by Staining

with ethidium bromide.

0.058 Isolation of intact BHV-1 viral DNA of the live
attenuated vaccine Strain can be performed as previously

described (Inman et al., 2001B, Inman et al., 2002). Briefly,
MDBK cells can be infected with the BHV-1 Strain obtained

from Pfizer at a multiplicity of infection of approximately
10. The clarified lysate can be pelleted using a 30% sucrose/

cine can be injected into the flank (caudal muscle mass) or
the neck (brachiocephalicus muscle) using 6.5 logo
TCIDso/ml of the virus. An 18 gauge needle (1.5 inch) can

be used for all IM injections, and the injection can contain
approximately 0.5 ml. Because the attenuated virus can
grow efficiently in the nasal cavity a robust BHV-1 specific
antibody response occurs in infected calves. However, the
clinical Symptoms and disease are not significant. The
construction of a LR mutant and route of vaccination

provided above are exemplary only, and any Suitable means
known in the art may be used in the practice of the present
invention

0060 Method of Use: Vaccines for Non-Herpes Viral and
Bacterial Pathogens
0061 Novel vaccines based on live BHV-1 attenuated by
mutation in the latency-related gene Such that the virus will
not reactivate from latency, may be used to provide vaccines
for a variety of viral and bacterial pathogens. Recombinant
nucleic acids may be inserted into any region of the viral
genome of attenuated BHV-1 strains of the present invention
which is non-essential for infection of the host, using
methods known in the art. For example, without limitation,

two Such approaches are: 1) insertion of recombinant nucleic

acid form the pathogen in the mutated LR gene locus Such
that expression is driven by the LR promoter to which it is

operably linked; and 2) insertion of recombinant nucleic
acid from the pathogen gene into a glycoprotein locus of an
LR mutant virus, and the expression of the pathogen nucleic
acid driven by a foreign promoter to which it is operably

linked.

0062 For the first approach, the pBlueL/mLAT plasmid
(Inman et al., 2001B) is modified to contain a unique PacI

restriction enzyme site at nucleotide 781 of LR sequences

(the first SphI site that was used to insert the mutant oligo).

Genes from these pathogens are cloned and PacI sites added
to the termini of these fragments. This approach permits
expression of the foreign gene operably linked to the LR
promoter in the context of the BHV-1 genome.
0063 For the second approach, recombinant nucleic acid

of other pathogens (or homologous nucleic acid of other
BHV-1 antigens) are inserted into the glycoprotein C (gC) or
glycoprotein E (gE) locus in the context of the LR mutant
Virus. The gC and gF loci are chosen because these genes are
not important for growth of the virus in cultured cells, thus
readily permitting construction of recombinant viruses. The
human cytomegalovirus promoter can be used to drive
expression of the respective genes from other pathogens as
this promoter is expressed efficiently during herpes simplex

TE cushion (25,000 rpm. for 2 h in a Beckman Lt.-65 using
an SW28 rotor at 4° C). Virions can be disrupted with SDS,
RNAse treatment, followed by proteinase K, and extraction
with phenol/chloroform/isoamyl alcohol (50:48:2). The

virus type 1 (HSV-1) acute infection, and thus can be

integrity and quantity of viral DNA is determined by 1%
agarose gel electrophoresis. Stocks of virus can be prepared

include, without limitation: bovine viral diarrhea virus

in MDBK cells as described previously (Inman et al.,
2001 B; Inman et al., 2002; Jones et al., 2000).
0059 Vaccination of animals with the live attenuated

vaccines of the present invention can be conducted by means

well known in the art (Jones et al., 2000). Briefly, for
intranasal instillation, calves can be inoculated with approxi
mately 6.5 logo TCIDs/ml of the respective modified live
vaccine strains. For IM vaccination, the modified live vac

expected to be expressed efficiently during BHV-1 produc
tive infection.

0064 Pathogens that are candidates for this approach

(BVDV), bovine respiratory virus (BRSV), bovine corona
“Shipping Fever” (Pasteurella haemolytica, Pasteurella
multocida, and Haemophilus Somnus for example). For the

Viruses, and bacterial Strains commonly associated with

Viruses listed, Structural proteins are used for foreign expres
Sion. For the bacterial pathogens, immunogenic Surface
proteins are used.
0065. Following vaccination of calves, a specific immune
response is induced against BHV-1 and the gene from the
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respective foreign pathogen. This immune response is deter
mined by measuring antibody responses.
EXAMPLES

0.066 The present invention is further described in the
following examples, which are offered by way of illustration
and are not intended to limit the invention in any manner.
Standard techniques well known in the art or the techniques
specifically described below are utilized.

were stored at -80 C. in 2 ml of tissue culture medium

Supplemented with 10 ug of amphotericin B per ml (Fun
gizone) and 45 ug of gentamicin per ml. Samples were
thawed quickly in a 37 C. water bath, vortexed, and
centrifuged (1,500xg for 10 min). All titrations were per
formed with 10-fold serial dilution and plated in quadrupli
Cate.

0073 Virus was isolated from TG by mincing 0.5g of
tissue, Suspending the tissue in 9 ml of Dulbecco's modified

EXAMPLE 1.

Eagle's medium (DMEM), and homogenizing the tissue
with a tissue grinder (Polytron, Switzerland). One milliliter

Materials and Methods

of fetal bovine Serum was added, and the homogenate was
Subjected to three freeze-thaw cycles with a dry ice-ethanol
bath. After the last cycle, the homogenate was centrifuged at

0067 A. Virus and Cells
0068 Bovine kidney cells (MDBK; ATCCCCL-22) were

plated at a density of 5x10 per 100-mm plastic dish in
Earle's modified medium supplemented with 5% fetal

bovine serum (FBS), penicillin (10 U/ml), and streptomycin
(100 lug/ml).
0069. The Cooper strain of BHV-1 (wt virus) (ATCC
VR-864) was obtained from the National Veterinary Ser
vices Laboratory, Animal and Plant Health Inspection Ser
vices, Ames, Iowa. A complete description of the LR mutant

virus has been previously described (Inman et al., 2001B
incorporated in full herein, by reference). Briefly, the LR
mutant virus was developed by replacing wt (Cooper Strain)
LR gene Sequences with an oligonucleotide that contains a
unique EcoRI restriction Site and three Stop codons in each

reading frame (FIG. 2). In transiently transfected cells, a

plasmid with this mutation does not express detectable

levels of the LR protein, but does express LR-RNA (Ciacci
Zanella et al., 1999). Viral stocks were prepared by infecting
MDBK cells with a multiplicity of infection (MOI) of 0.001

from a plaque-purified virus. Virus was titrated on MDBK
cells by using 10-fold dilutions and determining the 50%

tissue culture infectious dose (TCIDs) or PFU.
0070 B. Animal Experiments.
0071 BHV-1-free crossbred calves (-250 kg) were ran

domly assigned and housed in isolation rooms to prevent
croSS contamination. Calves were anesthetized with Rom

pun (approximately 1 mg/kg of body weight; Bayer Corp.,
Shawnee Mission, Kans). Calves were then inoculated with

1 ml of a solution containing 107 PFU of the indicated virus
total of 4x107 PFU per animal as described previously

per ml in each nostril and eye, without Scarification, for a

(Schang and Jones, 1997; Winkler et al., 1999; Winkler et
al., 2000). Experiments with animals were performed in
accordance with the American ASSociation of Laboratory
Animal Care guidelines. At 60 days postinfection (dpi)
(latency), calves were injected intravenously with 100 mg of
DEX as described previously (Winkler et al., 2000). Addi
tional intramuscular injections (25 mg) of DEX were given
at 2 and 4 days after the initial intravenous injection of DEX
to ensure that reactivation occurs. We have previously
demonstrated that multiple injections of DEX enhance shed

ding of virus (Jones et al., 2000). Calves were housed under
Strict isolation containment and given antibiotics before and
after BHV-1 infection to prevent secondary bacterial infec
tion.

0.072 Nasal Swabs, ocular Swabs, and serum samples
were taken at the designated times. Nasal and ocular Swabs

2,000 rpm (Jouan CR412 centrifuge) for 30 min at 4°C. The
Supernatant from the TG homogenate was Subsequently used

to infect MDBK cells. The TG Supernatant (125 ul) was
added to 500 ul of medium (1:5 dilutions), and then 1:5
serial dilutions were made. One hundred microliters of each

dilution was added in quadruplicate to a 96-well plate. One

hundred microliters of MDBK cells (10 cells) was added to

each well. After 4 days of incubation, cells were fixed and
then stained with formaldehyde-bromophenol blue. Virus
titers were measured with the 50% end point assay as

described previously (Inman et al., 2001B).
0074 C. Nucleic Acid Tissue Extraction
0075 RNA and DNA extractions from MDBK cells or
TG were performed as previously described (Jones et al.,
2000; Schang and Jones, 1997).
0.076 D. Reverse Transcription of RNA to Obtain cDNA
0077 Reverse transcription (RT) was performed essen
tially as previously described (Jones et al., 2000). Briefly, 4
lug of RNA was treated with DNase, and after inactivation,
the RNA was reverse transcribed with random hexamers as

primers. As a control for DNA contamination in the RNA
samples, DNase-treated RNA was mixed with the RT reac
tion mix lacking reverse transcriptase. Two microliters was
used for PCR.

0078 E. PCR
0079 PCR was performed on the extracted DNA and
synthesized cDNA with the indicated primer pairs p4(nucle
otide nt) 873, 5'CGTGTATTTGCGACCCCCAGCCT3'
(SEQ ID NO:1)) and p5 (nt 596, 5'GCCAGACCAAAC
CCCCCGCA3' (SEQ ID NO:2)) (Inman et al., 2001B;
Schang and Jones, 1997). Actin, L3B, and gC primers have
been described previously (Hossain et al., 1995; Inman et
al., 2001B; Jones et al., 2000; Schang and Jones, 1997). The
gC forward primer is 5' AAAGCCCCGCCGAAGGAG
(SEQ ID NO:3) (bp 550 of the BHV-1 gC gene). The gC
reverse primer is 5'TACGAACAGCAGCACGGGC (SEQ
ID NO:4) (bp 756 of BHV-1 gC gene). The forward bovine
growth hormone (gH) primer is 5' GCTTTCGCCCT
GCTCTGCC (SEQ ID NO:5) (bp 994 of the bovine growth
hormone gene). The reverse gH primer is 5'TCCTGCCTC
CCCACCCCTA (SEQ ID NO:6) (bp 1155 of the bovine
growth hormone gene). After a hot start, each cycle con
sisted of 95° C. for 1 min, 60° C. for 1 min, and 72 C. for

2 min (30 cycles total). To ensure complete elongation of
amplified products, the reaction was incubated at 72 C. for
an additional 10 min. For some studies, the PCR products
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were digested with EcoRI, electrophoresed on a 2% agarose
gel, and the DNA was visualized by staining with ethidium
bromide.

0080 F. Direct Fluorescence Assay for the Detection of
BHV-1

0081 For the direct fluorescence assay (FA), a 24-well

plate of MDBK cells was infected with clarified viral lysate.
Twenty-four hours later, cell monolayers were fixed for 5

min with ice-cold methanol-acetone (50:50) and then
allowed to dry. A 1:50 dilution of direct conjugate (anti
BHV-1-specific antibody-fluorescein isothiocyanate FITC
conjugate; American Bioresearch, Milton, Tenn.) was
added to the fixed cells and incubated at 37 C. for 30 min.

The monolayers were washed twice with phosphate-buff
ered Saline. The presence of virus was visualized with an
FITC filter.

0082) G. BHV-1-Specific Neutralizing Antibodies
0083) The Veterinary Diagnostic Service, University of
Nebraska, Lincoln, measured neutralizing antibody titers
with the Cooper Strain as the Stock virus, using Standard

designed to allow for WT levels of blCPO expression. The
entire promoter and coding region of the LR gene was
cloned into the pBlueBachisA vector as described previ

ously (Inman et al., 2001B). A total of 825 bases from the
adjacent HindIII L fragment (Inman et al., 2001A) were

cloned upstream of the LR promoter to ensure that efficient
homologous recombination occurred. The LR sequences

between the two SphI sites (nt 781 to 812) were replaced

with the mutant oligonucleotide. The mutant oligonucleotide
contains the first in-frame ATG of ORF2, a unique EcoRI
restriction site to facilitate Screening, and three Stop codons
that are in each reading frame. In transiently transfected
cells, this LR mutant gene construct expresses the LRRNA,
but the protein detected by a peptide antibody directed

against the N terminus of LR ORF2 (P2) is not detected
(Carter et al., 1989; Hariharan et al., 1993).
0088 BHV-1 DNA was extracted from infected cells, and

its integrity was examined by agarose gel electrophoresis.
BHV-1 DNA is not very infectious when transfected into
cultured bovine epithelial cells. Efficient plaque formation
was not observed at 14 days posttransfection, a time when
cells were lifting off the plates. When BHV-1 DNA and

materials and methods.

plasmids encoding b|CPO (Inman et al., 2001C) or HSV-1

0084. H. In Situ Hybridization
0085) DNA probes specific for BHV-1 gC, ribonucleotide
reductase, blCP0, and the LR gene were used. Labeling of
the probes and hybridization Steps were performed as pre

ICPO were cotransfected into bovine cells, efficient plaque
formation was consistently observed 48 h after transfection.
A plasmid expressing HSV-1 ICPO was used for these
studies because bCPO sequences overlapped the LR mutant
region, and thus we were concerned this might reduce the
efficiency of homologous recombination.
0089. The viral genome was cotransfected into bovine
epithelial cells with HSV-1 ICPO and the plasmid containing

viously described (Winkler et al., 1999; Winkler et al.,
2000). After hybridization, slides were washed twice in
4xSSC (1xSSC is 0.15 MNaCl plus 0.015M sodium citrate)
for 5 min at room temperature, once in 2XSSC at 40 C.,

once in 0.5xSSC at 40° C., twice in 2XSSC at room
temperature, twice in 0.5xSSC at room temperature, and

once in buffer I (100 mM maleic acid, 150 mM NaCl pH
7.5). The conjugate antibody Step and reaction development
were also performed as previously described (Winkler et al.,
1999; Winkler et al., 2000).
EXAMPLE 2

Construction of a BHV-1 LR Mutant Virus

0086) To determine whether BHV-1 LR gene products
play a role in virus growth and/or latency, a BHV-1 LR
mutant virus that contains Stop codons near the 5' terminus
of the LR transcript was constructed and tested in cultured
cells and calves.

0087. The LR gene is transcribed antisense with respect
to the immediate-early (IE) and early (E) gene transcript
(IE/2.9 and E/2.6) that encodes b|CP0. The lytic start site for
the LR RNA is at nt 724 (Ahmed et al., 2002; Hariharan et
al., 1993), and the first in-frame ATG for LR open reading
frame 2 (ORF2) is at nt 783 to 785, whereas the stop site for
bICPO is at nt 956 (LR numbers) (Devi-Rao et al., 1994;
Rock et al., 1987A; Rock et al., 1987B; Sawtell, 1997),
which complicates construction of an LR mutant Virus. The
cis-acting sequences that regulate poly(A) addition for the
transcript that encodes blCP0 are also near Sequences that
contain the LR gene TATA box. This prevented insertion of
a reporter gene near the Start Site of LR gene expression or
an extensive deletion of LR gene Sequences. Consequently,
we inserted three Stop codons to prevent LR protein expres
Sion in all three reading frames. This mutation was also

the mutant oligonucleotide (pBlueL/mLAT). Plaques were

isolated and Screened for insertion of the mutant oligonucle
otide sequence by PCR using the p4 and p5 primers. The
amplified products were then digested with EcoRI. If
homologous recombination between the LR mutant plasmid

and the viral genome occurred, two bands (105 and 193 bp)
virus yielded a single band (298 bp) as expected. After the

would be observed following digestion with EcoRI. WT
potential LR mutants were Subjected to three rounds of
plaque purification, the same banding pattern was observed,
demonstrating that the mutant virus from a plaque was not
contaminated with WT virus and was stable. Several plaques
containing the mutant were Selected and plaque purified two
more times to ensure they were not contaminated with WT

WUS.

0090. To ensure that a resulting phenotype was not due to
Secondary Site mutations, a rescued virus was constructed

(LR rescued virus). The LR mutant viral genome was
cotransfected with the WT LR gene cloned into pBlueBa
cHisA(pblueL/LAT) and a plasmid encoding HSV-1 ICPO
into bovine cells. The p4 and p5 primers were used to
identify amplified products that were not digested by EcoRI,
which was indicative of the LR WT gene. Viral sequences
encompassing the manipulated regions of the LR gene in the
LR mutant and LR rescued virus were Sequenced and
contained the expected Sequences.
EXAMPLE 3

Analysis of the BHV-1 LR Mutant Virus in MDBK
Cells

0091) Infection of MDBK cells with BHV-1 Cooper
strain produces visible cytopathic effects by 7 to 10 hp.i.

Sep. 23, 2004

US 2004/0185056A1

followed by efficient plaque formation. IE gene expression
can be detected within 1 to 2 hp.i. Although not statistically
Significant, growth curves Suggested that the mutant released
virus slightly faster from MDBK cells early in infection at
an MOI of 1. However, the end point titers were consistently
the same. At an MOI of 5, there were no differences in the
titers of cell-associated and released virus. It was consis

tently observed that resting cells or cells that were too
confluent did not yield as much virus as actively growing
cells. However, the LR mutant and WT virus had similar

growth properties in MDBK cells. LR mutant, LR rescued,
and WT viruses also had similar growth properties in rabbit

epidermal (CCL-68; ATCC), rabbit lung (CCL-193; ATCC),
rabbit skin fibroblasts (CRL-1414; ATCC), and bovine epi
dermal cells.

EXAMPLE 5

Growth of LR Mutant Virus in TG of Acutely
Infected Calves

0094 BHV-1 LR mutant virus containing stop codons
near the 5' terminus of the LR transcript (LR mutant) where
constructed, as previously described (Inman et al., 2001B).
The LR mutant grew to similar titers relative to wt or
LR-rescued virus in the nasal cavity of calves and cultured
bovine cells. However, the LR mutant shed approximately 4
logs less infectious virus from eyes of acutely infected
calves compared to wt or LR-rescued virus, Suggesting the
LR gene plays a role in acute virus growth in certain bovine
tissue.

0.095 Presence of infectious virus. To test whether calves

0092. The LR RNA is antisense to the IE and E transcript
that is translated into b|CP0(Jones 1998), suggesting blCP0
expression could be altered by the mutation within the LR
gene. Since bCP0 is essential for productive viral replica
tion (Fraefel et al., 1994, Inman et al., 2001C; Koppel et al.,
1996), expression of blCP0 in the WT, LR rescued, and LR
mutant viruses following infection of MDBK cells were
compared. These Studies demonstrated that expression of
bICPO in MDBK cells infected with the LR mutant was at

least as high as in those infected with the WT or the LR
rescued virus.

infected with the LR mutant contained different amounts of

infectious virus in TG compared to calves infected with wt
BHV-1, calves were infected with the respective viruses, TG
were harvested at different times after infection, and infec

tious virus was measured in TG homogenates. Levels of
infectious virus in TG homogenates were measured by
incubating the Supernatants with MDBK cells. Cultures that
produced cytopathic effects were also Subjected to FA with
BHV-specific antisera as an independent verification that
cytopathic effects were due to virus infection and not non
Specific toxic effects of the TG homogenates. At 2 and 4 dpi,
calves infected with the LR mutant contained 10- to 100

EXAMPLE 4

fold less virus in TG homogenates compared to calves
infected with wt virus (FIG. 1). Infectious virus was not
detected in TG of calves infected with the LR mutant on 6

Construction of CJLAT

0093. The plasmid p1658 contains two HSV-1 DNA
restriction fragments. One restriction fragment (HpaI
EcoRV) corresponds to the region from 1800 to 161 nucle
otides upstream of the LAT start site (LAT nucleotides
-1800 to -161). The other restriction fragment (HpaI-Mlul)
corresponds to LAT nucleotides 1667 to 2850. A unique PacI
restriction Site was cloned between these restriction frag

ments (i.e., between LAT nucleotides -161 and +1667). PacI
linkers were added to the complete BHV-1 LR gene DNA,
which was then cloned into the above unique PacI restriction
site of p1658. The LR gene was a 1.9-kb HindIII-Sall
fragment derived from the HindIIID fragment of BHV-1

strain Cooper (BHV-1 nucleotides 1 to 1941) that contains
the LR promoter and the known coding sequences (Kutish et
al., 1990). The resulting plasmid, CJLATP1658, was
cotransfected with infectious dLAT2903 genomic DNA into
RS cells as we previously described for construction o other

HSV-1 mutants (Pering et al., 1994; Perng et al., 1996). After
homologous recombination between the HSV-1 DNA flank
ing the BHV-LR DNA in the plasmid and the genomic DNA
flanking the LAT deletion in dLAT2903, the cotransfection
mix was plated on RS cells, and Viral plaques were isolated.
Individual plaques were analyzed by restriction digestion
and Southern analysis. In the final chimeric virus, CJLAT,
the core LAT promoter and the region of the LAT gene
corresponding to the first 1.7-kb of the primary LAT tran
script of HSV-1 McKrae has been replaced by the BHV-1
LAT gene. CJLAT was triple plaque purified and its genomic
Structure was confirmed by additional restriction digestion
Southern analysis.

dpi. FA-positive Samples were detected at 6 dpi in LR
mutant-infected calves and 10 dpi in calves infected with the

wt (data not shown), but the amount of virus was too low for
titration.

0096 Presence of LR mutant genome. To verify that the
LR mutant genome was present in TG of calves infected
with the LR mutant, PCR analysis was performed. DNA was
prepared from calves infected for 6 or 10 dpi and Screened
for the presence of the mutant by PCR with the p4 and p5
primerS. Amplified products were then digested with EcoRI.
Calves infected with the LR mutant contained two bands

(105 and 193 bp) that were detected following digestion
with EcoRI. The presence of wt virus yields a single band of
298 bp, while LR mutant virus yields two bands migrating
at 105 and 193 bp. The LR mutant plasmid and a plasmid
with the wt LR gene were used as positive controls to show
the positions of the expected products. PCR of representa
tive samples from calves infected for 6 or 10 days demon
strates that only the inoculated virus was detected in the TG.
In Summary, this Study demonstrated that, during acute
infection, lower levels of infectious virus were present in TG
of calves infected with the LR mutant.

0097 Analysis of BHV-1 DNA in calves infected with
the LR mutant or wt DNA. In situ hybridization was
performed with probes that specifically bind to four viral

genes (Winkler et al., 1999; Winkler et al., 2000). Thin

sections were prepared from TG of calves infected with the

LR mutant or wt virus at 10 (end of acute infection or
establishment of latency) or 60 (latency) dpi. In situ hybrid
ization was performed as described in Example 1. In Situ
positive neurons in TG were consistently detected in thin
sections prepared from calves infected with wt virus at 10
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and 60 dpi. We estimated that less than 5% of the total
neurons contained viral DNA, as judged by in situ hybrid
ization. In contrast, DNA-positive neurons were not detected
by in situ hybridization with TG thin sections prepared from
calves infected with the LR mutant for 10 or 60 days after
infection, This Study Suggested that neurons with high
copies of viral DNA were not present in TG of calves
infected with the LR mutant.

0098. To further compare the levels of viral DNA in TG
of calves infected with the wt virus or the LR mutant, a

semiquantitative PCR was performed as described in
Example 1. PCR primers were used to detect BHV-1 gC

DNA and bovine growth hormone (gH). PCR products were

electrophoresed on 2% agarose gels, and the DNA was
stained with ethidium bromide. DNA prepared from: TG of
a mock-infected calf, MDBK cells infected with BHV-1

(MOI=1) for 24 h; and from BHV-1 virions (purified) were

included as controls. For each DNA sample, 1 lug of DNA
was used for PCR. 20 ng of purified viral DNA was used for
PCR.

0099 We focused on samples prepared from latently
infected calves 60 days after infection (60 dpi) or during the
early stages of reactivation (24 and 48 h after Single intra
venous injection with DEX). As expected, wt viral DNA was
readily detected in TG of latently infected calves and at 24
or 48 h after DEX treatment. In contrast, TG prepared from
calves latently infected with the LR mutant did not contain
detectable levels of viral DNA. At 24 h after DEX treatment,

neither of two calves latently infected with the LR mutant
contained detectable levels of viral DNA. At 48 h after DEX

treatment, one of three calves latently infected with the LR
mutant contained detectable levels of viral DNA. Under the

conditions of this PCR assay, we were able to detect
approximately 200 to 400 copies of viral DNA per ug of total

DNA. In Summary, two independent assays (in Situ hybrid
ization and PCR) demonstrate that calves latently infected

with the LR mutant contained less viral DNA in TG.
EXAMPLE 6

LR-RNA Expression in Calves Latently Infected
with the LR Mutant

0100. In theory, the LR mutant should express LR-RNA,
but not proteins because of the three stop codons (Inman et
al., 2001B). RNA was extracted from TG of infected calves

or MDBK cells as described in Example 1. cDNA was
generated with random primers and PCR was performed
with Specific primerS. Primers that amplify a Segment of the
B-actin transcript flank an intron, which allows for detection

of contaminating DNA as previously described (Inman et al.,
2001B). L3B primers were used to detect the LR transcript.

Primers that amplify gC RNA were used to verify that calves
were in the latent phase of infection. When reverse tran
scriptase was omitted during cDNA synthesis, no PCR
product was detected. In productively infected bovine cells,
the LR mutant expressed abundant levels of LR-RNA.
LR-RNA expression was examined in TG of calves infected

with the LR mutant at 60 dpi (latency). RT-PCR was

performed with primers that specifically amplify LR-RNA

(L3B) as described previously (Ciacci-Zanella et al., 1999;
Hossain et al., 1995; Jones et al., 2000). LR-RNA was

detected in two of two calves infected with the LR mutant

and, as expected, in two of two calves infected with the wt

at 60 dpi. gC RNA was not detected by RT-PCR in latently
infected calves, demonstrating that high levels of productive

infection were not occurring in TG during latency (60 days
after infection).
EXAMPLE 7

Effect of DEX on Reactivation of the LR Mutant

0101 Treatment of latently infected rabbits (Rock et al.,
1992) or calves (Jones et al., 2000; Sheffy and Davies, 1972)

with DEX consistently reactivates BHV-1 from latency.
Consequently, Virus Shedding occurs in ocular or nasal
cavities, and virus-specific antibodies increase. A prelimi
nary Study was performed with two calves latently infected
with the LR mutant, two calves infected with wt virus, and

two calves infected with the LR-rescued virus. Following a

single intravenous injection of DEX (100 mg), we detected

reactivation in calves latently infected with wt or the LR
rescued virus, but not the two calves infected with the LR

mutant, Suggesting the LR mutant was not capable of
reactivating. To confirm this result, a larger Study was

performed with an initial intravenous injection of DEX (100
mg) followed by two intramuscular injections of DEX (25
mg) to ensure that reactivation occurred efficiently. Our

previous Studies demonstrated that multiple injections of
DEX allowed efficient reactivation of a temperature-sensi
tive mutant of BHV-1, which is used as a modified live

vaccine and is severely attenuated (Jones et al., 2000).
0102 Neutralizing antibody titers were measured after
DEX treatment to determine if reactivation occurred. Serum
was collected from calves at the indicated times and Stored

at -20° C. until tested. Standard testing was performed with
constant amounts of virus (Cooper strain) and twofold Serial

dilutions of the serum. The Veterinary Diagnostic Services,
University of Nebraska, Lincoln, performed the assay. AS
expected, a dramatic increase in Virus-specific antibodies

was detected in animals infected with wt or LR-rescued

virus after DEX-induced reactivation (FIG. 3), indicating

that virus replication and Shedding occurred. A five- to
Sixfold increase in antibody titers was detected, which is
consistent with reactivation from latency. In contrast, an
increase in Virus-specific antibodies was not observed when
calves latently infected with the LR mutant were treated

with DEX.

0103) To confirm the neutralizing antibody results, ocular
and nasal Swabs were collected from each calf at the

designated times after treatment with DEX. Infectious virus
in Swabs was detected by inoculating MDBK cells with a
1:20 dilution of the Swab medium Solution. FA was used to

confirm the presence of infectious BHV-1 in cultures con
taining cytopathic effects. AS expected, during latency, wit,
rescued, or LR mutant virus was not detected in Swabs on the

day of DEX treatment (day 0). At 4 and 7 days after DEX
treatment, infectious virus was detected in Swabs obtained

from Six of Seven and Seven of Seven calves latently infected

with wt virus (FIG. 4). At 4 and 7 days after DEX treatment,

infectious virus was detected in four of four calves infected

with the rescued virus. At these time points, infectious virus
was detected in nasal and ocular Swabs of calves Shedding
wt and LR-rescued virus. To simplify the data, the ocular
and nasal results were combined. In Sharp contrast, infec
tious virus was not detected in Seven of Seven calves latently
infected with the LR mutant at any time point tested.
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Infectious virus was not detected in nasal or ocular Swabs of

any calf after 10 days postreactivation. These Studies dem
onstrated that the LR mutant did not reactivate from latency
following multiple injections of DEX.

0115 Coffin et al., 1998. The herpes simplex virus
2-kb latency associated transcript (LAT) leader
Sequence allows efficient expression of downstream
proteins which is enhanced in neuronal cells: possible
function of LAT ORFs. J. Gen. Virol. 79:3019-3026.

DEPOSIT INFORMATION

0104. The live, attenuated BHV-1 strain has been depos
ited with the American Type Culture Collection (ATCC),
10801 University Boulevard, Manassas, Va. 20110-2209,
USA, on
, in accordance with the Budapest Treaty
and has been accorded Accession Number

0105 From the foregoing it will be seen that this inven
tion is one well adapted to attain all ends and objectives
herein-above Set forth, together with the other advantages
which are obvious and which are inherent to the invention.

0106 Since many possible embodiments may be made of
the invention without departing from the Scope thereof, is to
be understood that all matters herein set forth or shown in

the accompanying drawings are to be interpreted as illus
trative, and not in a limiting Sense.
0107 While specific embodiments have been shown and
discussed, various modifications may of course be made,
and the invention is not limited to the Specific forms or
arrangement of parts and Steps described herein, except
insofar as Such limitations are included in the following
claims. Further, it will be understood that certain features

and Sub-combinations are of utility and may be employed
without reference to other features and Sub-combinations.

This is contemplated by and is within the scope of the
claims.
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SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 8
<21 Oc
<211
<212>
<213>
<22O >
<223>

<400

SEQ ID NO 1
LENGTH
TYPE

23
DNA

ORGANISM: Artificial
FEATURE

OTHER INFORMATION: p. 4 primer
SEQUENCE: 1

cgtgt atttg cq accoccag cott

23

SEQ ID NO 2
LENGTH
TYPE

2.0
DNA

ORGANISM: Artificial
FEATURE

OTHER INFORMATION: p5 primer
<400

SEQUENCE: 2

gccagaccala accoccc.gca

SEQ ID NO 3
LENGTH
TYPE

18
DNA

ORGANISM: Artificial
FEATURE

OTHER INFORMATION: forward gC primer
<400

SEQUENCE: 3

aaa.gc.ccc.gc cqaaggag

18

SEQ ID NO 4
LENGTH
TYPE

19
DNA

ORGANISM: Artificial
FEATURE

OTHER INFORMATION: reverse gC primer
<400

SEQUENCE: 4

tacgaac agc agcacgggc
<210

SEQ ID NO 5

&2 11s LENGTH 19
&212> TYPE DNA

<213> ORGANISM: Artificial

19
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-continued
&220s FEATURE

<223> OTHER INFORMATION: forward gH primer
<400

SEQUENCE: 5

gcttitc.gc.cc td citctg.cc

19

SEQ ID NO 6
LENGTH
TYPE

19
DNA

ORGANISM: Artificial
FEATURE:

OTHER INFORMATION: reverse gH primer
<400

SEQUENCE: 6

toctg.cctcc ccaccocta

19

SEQ ID NO 7
LENGTH
TYPE

37
DNA

ORGANISM: Bovine herpesvirus 1
<400

SEQUENCE: 7

gcatgcgcga cct gggcc at aaaag.ccc.cg cqcatgc

37

SEQ ID NO 8
LENGTH
TYPE

2.8
DNA

ORGANISM: Artificial
FEATURE:

OTHER INFORMATION: mutant oligonucleotide
<400

SEQUENCE: 8

gcatgcagaa ttctagittag ttago atg

What is claimed and desired to be secured by Letters Patent
is as follows:

1. A vaccine composition against a viral or bacterial
pathogen, comprising a viral vector, wherein Said viral
vector is a mutant recombinant BHV-1 Strain comprising:

a. a mutation in the latency-related (LR) gene, whereby no
detectable reactivation from latency occurs, and
b. an expressable recombinant nucleic acid encoding an
antigen from Said viral or bacterial pathogen, wherein
expression of Said antigen induces immunological
response against Said viral or bacterial pathogen.
2. The vaccine composition of claim 1, wherein Said viral
vector comprises modified BHV-1 strain on deposit with the
American Type Culture Collection as Accession No.
3. The vaccine composition of claim 1, wherein Said
mutation in the LR gene is accomplished by chemical
Synthesis or artificial manipulation of isolated Segments of
nucleic acid.

4. The vaccine composition of claim 1, wherein Said
mutation in the LR gene is spontaneous or a Selected,
naturally occurring mutation.
5. The vaccine composition of claim 1, wherein the live,
attenuated BHV-1 strain comprises a modified BHV-1 strain
other than the BHV-1 strain on deposit with the American
Type Culture Collection as Accession No. VR-864.

28

6. The vaccine composition of claim 1, wherein Said
mutated LR gene comprises the nucleotide Sequence of SEQ
ID NO:8.

7. The vaccine of claim 1, wherein said expressable
recombinant nucleic acid is inserted in Said mutated LR gene
locus, whereby expression of the recombinant nucleic acid
is driven by the LR promoter.
8. The vaccine of claim 1, wherein said expressable
recombinant nucleic acid is inserted in a glycoprotein locus
of the viral vector, whereby expression of the recombinant
nucleic acid is driven by a heterologous promoter.
9. The vaccine composition of claim 1, wherein said
vaccine is adapted for administration by a mode Selected
from the group consisting of intranasal instillation, intra
muscular, ocular, intraperitoneal, and Subcutaneous.
10. The vaccine composition of claim 1, wherein said
Viral or bacterial pathogen is Selected from the group con
Sisting of bovine herpesvirus 1, bovine viral diarrhea virus,
bovine respiratory virus, bovine corona virus, Pasteurella
haemolytica, Pasteurella multocida, and Haemophilus SOm
S.

11. A method of modulating the immune response to a
Viral or bacterial infection, which comprises administering a
vaccine composition according to claim 1.
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12. A method of vaccinating a mammal in need thereof
against a viral or bacterial pathogen, which comprises
administering to Said mammal a vaccine composition
according to claim 1.
13. The method of claim 12, wherein said mammal is an

ungulate.
14. The method of claim 13, wherein said ungulate is
Selected from the group consisting of bovines, buffalo,
sheep, and deer.
15. The method of claim 12, wherein said viral or bacte

rial pathogen is Selected from the group consisting of bovine
herpesvirus 1, bovine viral diarrhea virus, bovine respiratory
virus, bovine corona virus, Pasteurella haemolytica, Pas
teurella multocida, and Haemophilus SOmnus.
16. A recombinant viral vector comprising SEQ ID NO:8
and a recombinant nucleic acid fragment capable of encod
ing an antigen from a viral or bacterial pathogen.
17. The recombinant viral vector of claim 16, wherein

Said viral or bacterial pathogen is Selected from the group
consisting of bovine herpesvirus 1, bovine viral diarrhea

Virus, bovine respiratory virus, bovine corona virus, Pas
teurella haemolytica, Pasteurella multocida, and Haemo
philus SOmnus.
18. A method for effecting the treatment of a viral or
bacterial infection, which comprises administering to a
mammal in need of Said treatment, an effective amount of
the vaccine of claim 1.

19. The method of claim 18, wherein said mammal is an

ungulate.
20. The method of claim 19, wherein said ungulate is
Selected from the group consisting of bovines, buffalo,
sheep, and deer.
21. The method of claim 18, wherein said viral or bacte

rial pathogen is Selected from the group consisting of bovine
herpesvirus 1, bovine viral diarrhea virus, bovine respiratory
virus, bovine corona virus, Pasteurella haemolytica, Pas
teurella multocida, and Haemophilus SOmnus

